PolyPid (NASDAQ:PYPD – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $14.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 294.37% from the company’s current price.
PolyPid Price Performance
Shares of NASDAQ PYPD opened at $3.55 on Wednesday. The company has a debt-to-equity ratio of 1.95, a quick ratio of 0.95 and a current ratio of 0.95. PolyPid has a 12-month low of $2.95 and a 12-month high of $9.20. The firm’s 50-day moving average price is $3.52 and its 200-day moving average price is $4.09.
PolyPid (NASDAQ:PYPD – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.51) by $0.26. On average, equities research analysts expect that PolyPid will post -4.39 EPS for the current year.
PolyPid Company Profile
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Featured Stories
- Five stocks we like better than PolyPid
- Bank Stocks – Best Bank Stocks to Invest In
- Analysts See 180% Upside for Rent the Runway: Should You Buy?
- The 3 Best Blue-Chip Stocks to Buy Now
- Ready for Growth? Barrick Gold Stock Could Be the Answer
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Trade Like a Member of Congress With These 2 ETFs
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.